zurück

EU-HTA

#

Fallacy 7: JCA is the first HTA submission in Europe. Really?

19.03.2026
Most national HTA assessment start once a product is approved. But some begin earlier ...
#

Update on sasanlimab and EU HTA

12.03.2026
Pfizer has withdrawn the EU marketing authorisation application for sasanlimab, which in turn means that the associated Joint Clinical Assessment (JCA) has been discontinued ...
#

Fallacy #6: RWE fills the gaps in clinical evidence. Really?

06.03.2026
Real-World Evidence, RWE, often sounds like a solution to many evidence challenges ...
#

A major step forward for patients

02.03.2026
Ipsen’s tovorafenib for paediatric low-grade glioma received a positive CHMP opinion ...
#

PART 11: Be ready for the phase after JCA submission

26.02.2026
JCA submission is not the finish line – it’s the start of the most intense phase ...
#

Fallacy 5: EU HTA affects only Market Access and HEOR – really?

17.02.2026
Usually, EU HTA tasks are handled by Market Access and HOER ...
#

Part THREE: insights into our projects

12.02.2026
From challenging local market accesses into a global approval strategy – powered by our network ...
#

Access Briefing Q4/25 - German Insights

11.02.2026
Within the Access Briefing Q4 2025, Ecker + Ecker delivers exciting decisions and developments from the German HTA landscape ...
#

JCA update available

04.02.2026
We provide you with the latest regulatory update from the EMA, announced last week ...
#

Fallacy 4: PICO is driven by payer archetype – really?

03.02.2026
PICO scoping is quite complex, and 27 member states (plus 3 EEA countries) are a lot ...
#

Our HTA insights Q4 2025 are now available 🌍

30.01.2026
Together with our local partners and experts, we’ve analyzed HTA decisions from 13 countries across Europe and Canada from October to December 2025 ...
#

Tool News PART 10: The European HTA landscape in one database

28.01.2026
Oncology products and Advanced Therapy Medicinal Products (ATMPs) are among the first drugs subjected to EU HTA ...

 

Ansprechpartner

Janine Leismann

Janine Leismann
Tel.: +49 (40) 41 33 081-26
j.leismann(at)ecker-ecker.de